Ollin Emerges From Stealth with $100M To Develop Eye Disease Bispecifics
OLN324 targets both VEGF and Ang2, the same mechanism of action as Roche’s Vabysmo, the Swiss giant’s multi-blockbuster treatment for wet macular degeneration and diabetic macular edema.
Ollin Emerges From Stealth with $100M To Develop Eye Disease Bispecifics Read More »
